Extended Low-Dose Apixaban Cuts Recurrent VTE in High-Risk Provoked Patients
核心洞察
A randomized, double-blind, placebo-controlled trial of 600 patients found extended low-dose apixaban (2.5 mg twice daily) reduced recurrent VTE from 10% to 1.3% versus placebo (HR 0.13; 95% CI 0.04–0.36).
The trial enrolled patients with provoked VTE and persistent risk factors who had completed at least three months of anticoagulation, a group with limited prior evidence guiding extended therapy.
Major bleeding was rare and did not differ significantly between groups, though clinically relevant nonmajor bleeding was numerically more frequent with apixaban.
Among patients with provoked venous thromboembolism (搜索) (VTE) who have ongoing risk factors, extending anticoagulation with low-dose apixaban substantially reduces the risk of recurrence, according to a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine.
The trial randomized 600 patients with provoked VTE and persistent risk factors—such as obesity, chronic lung disease, atherosclerotic cardiovascular disease, or autoimmune disease—who had completed at least three months of anticoagulation to either low-dose apixaban (2.5 mg twice daily) or placebo for an additional year. Recurrent VTE occurred far less often with extended apixaban than with placebo (1.3% versus 10%; hazard ratio [HR], 0.13; 95% confidence interval [CI], 0.04 to 0.36).
The study was conducted as a single-center, outpatient trial at Brigham and Women's Hospital. The findings address a recognized gap in clinical evidence, as provoked VTE is typically treated with three months of anticoagulation, but patients with ongoing risk factors may remain at higher risk for recurrence, and evidence guiding extended therapy in this group has been limited.
Safety Profile
Major bleeding was rare and did not differ significantly between the apixaban and placebo groups. However, clinically relevant nonmajor bleeding was numerically more frequent with apixaban. The authors note that limitations include the single-center design and limited power to evaluate outcomes across specific risk factors.
Clinical Implications
The bottom line of the review is that, in selected high-risk patients with provoked VTE, extended low-dose apixaban substantially reduces recurrence with a low risk of major bleeding. These results suggest that patients with provoked VTE and persistent risk factors may benefit from extended anticoagulation beyond the conventional three-month treatment period, supporting a more individualized approach to determining the duration of therapy.